Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia

References

• HirschSRKisslingWBaumlJPowerAO’ConnorRA 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophreniaJ Clin Psychiatry20026351652312088164
   PubMed Web of Science ®Google Scholar
• KaneJMCarsonWHSahaAREfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry20026376377112363115
   PubMed Web of Science ®Google Scholar
• VanelliMBursteinPCramerJRefill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chainPsychiatr Serv2001521248125011533402
   PubMed Web of Science ®Google Scholar
• MenzinJBoulangerLFriedmanMMackellJLloydJRTreatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid programPsychiatr Serv20035471972312719504
   PubMed Web of Science ®Google Scholar
• KaneJMDrug therapy: schizophreniaN Engl J Med199633434417494570
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: A comprehensive research synthesisAm J Psychiatry19991561686169610553730
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGAbrahamDKisslingWEfficacy and extrapyramidal effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trialsSchizophr Res19993551689988841
   PubMed Web of Science ®Google Scholar
• LeslieDLRosenheckRAUse of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictorsMed Care20013992393311502950
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice guideline for the treatment of patients with schizophreniaAm J Psychiatry1997154163
   Web of Science ®Google Scholar
• LehmanAFSteinwachsDMAt issue: Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendationsSchizophr Bull1998241109502542
   PubMed Web of Science ®Google Scholar
• Department of Veterans AffairsClinical Guidelines for Management of Persons with PsychosesWashington, D.CVeterans Health Administration1998
   Google Scholar
• DolderCRLacroJPDunnLBJesteDVAntipsychotic medication adherence: Is there a difference between typical and atypical agentsAm J Psychiatry200215910310811772697
   PubMed Web of Science ®Google Scholar
• ValensteinMCopelandLABlowFCPharmacy data identify poorly adherent patients with schizophrenia at increased risk for admissionMed Care20024063063912187177
   PubMed Web of Science ®Google Scholar
• DochertyJMahmoudRGroggAKozmaCAntipsychotic maintenance in schizophrenia: partial compliance and clinical outcomeSchizophr Res200360281282
   Web of Science ®Google Scholar
• LehmanAFKreyenbuhlJBuchananRWThe Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003Schizophr Bull20043019321715279040
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• RenXSQianSLeeAFHerzLMillerDRKazisLETreatment persistence: A comparison among patients with schizophrenia who were initiated on atypical antipsychotic agentsJ Clin Pharm Ther200631576516476121
   PubMed Web of Science ®Google Scholar
• HaynesRBurkeLEImproving patient adherence: state of the art, with a special focus on medication taking for cardiovascular disordersCompliance in Health Care and ResearchNew York, NYFutura Publishing Co2001321
   Google Scholar
• SclarDAAChinTLSkaerOkamotoMPNakahiroRKGillMAEffect of health education in promoting prescription refill compliance among patients with hypertensionClin Ther1991134894951934001
   PubMed Web of Science ®Google Scholar
• SclarDASkaerTLChinAOkamotoMPNakahiroRKGillMAUtility of a transdermal delivery system for antihypertensive therapyPart2Am J Med20019157S60S
   Google Scholar
• SteinerJFKoepsellTDFihnSDInuiTSA general method of compliance assessment using centralized pharmacy recordsMed Care1988268148233398608
   PubMed Web of Science ®Google Scholar
• LamoreauxJThe organizational structure for medical information management in the Department of Veterans Affairs: an overview of major health care databasesMed Care199634MS31448598686
   PubMed Web of Science ®Google Scholar
• RenXSQianSKazisLEAn alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health AdministrationNeuropsychiatr Dis Treat2007327728419300560
   PubMedGoogle Scholar
• McCombsJSNicholMBStimmelGLUse patterns for antipsychotic medications in Medicaid patients with schizophreniaJ Clin Psychiatry199960Suppl 1951110507275
   PubMed Web of Science ®Google Scholar
• CramerJARosenheckPEnhancing medication compliance for people with serious mental illnessesJ Nerv Ment Disord19991875355
   PubMed Web of Science ®Google Scholar
• CitromeLVolavskaJOptimal dosing of atypical anti-psychotics in adults: a review of the current evidenceHarv Rev Psychiatry20021028029112202454
   PubMed Web of Science ®Google Scholar
• WeidenPZygmundAThe road back: working with the severely mentally illJournal of Practical Psychiatry and Behavioral Health19973106110
   Google Scholar
• RenXSLeeAFHuangYHMillerDRQianSKazisLEAdjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophreniaJ Clin Pharm Ther2005a30657115659005
   PubMed Web of Science ®Google Scholar
• RenXSKazisLELeeAFPatients’ characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophreniaSchizophr Res2005b7716717715894460
   PubMed Web of Science ®Google Scholar